Cancer imaging agent Flucis® approved in the EU
Berlin, July 25, 2002 - Schering AG's (FSE: SCH, NYSE: SHR) cancer imaging agent Flucis® for PET(Positron Emission Tomography) imaging has been approved in the EU. The launch of Flucis® is expected within the next months, reference member state for the Mutual Recognition Procedure (MRP) was France.
"The launch of Flucis® in the EU for the expanding market segment of PET will further strengthen our core competence in in-vivo imaging," said Michael Rook, Head of Schering's Diagnostics & Radiopharmaceuticals business area. "With new developments such as Flucis® we will extend our leading role in research and marketing in the field of diagnostics and radiopharmaceuticals."
Flucis® can be used in a very broad spectrum of diagnostic processes such as diagnosis, staging, monitoring and the detection of recurrences of several oncologic indications including head and neck cancer, lung cancer and malignant lymphomas. Further oncologic indications of Flucis® include the staging and detection of recurrences from colorectal cancer and melanoma.
Flucis®, [18F] fludeoxyglucose, accumulates in cells with a high metabolic activity (e.g. cancer cells) by mimicking glucose. It is blocked in the cellular metabolic process and therefore remains trapped in the tumor cells allowing the monitoring with Positron Emission Tomography (PET)